- Early change in serum leucine-rich α-2-glycoprotein predicts clinical and endoscopic response in ulcerative colitis
-
Karashima R, Sagami S, Yamana Y, Maeda M, Hojo A, Miyatani Y, Nakano M, Matsuda T, Hibi T, Kobayashi T
- KMID: 2560297
- Intest Res.
- 2024 Oct;22(4):473-483.
- doi: 10.5217/ir.2023.00135
Background/Aims: Leucine-rich α-2-glycoprotein (LRG) is a new serum biomarker reflecting the disease activity of ulcerative colitis (UC), but its change during the acute phase has not been enough investigated. Methods:... -
- CITED
-
- Close
- SHARE
-
- Close
- Individualized treatment based on CYP3A5 single-nucleotide polymorphisms with tacrolimus in ulcerative colitis
-
Okabayashi S, Kobayashi , Saito E, Toyonaga T, Ozaki R, Sagami S, Nakano M, Tanaka J, Yagisawa K, Kuronuma S, Takeuchi O, Hibi T
- KMID: 2449963
- Intest Res.
- 2019 Apr;17(2):218-226.
- doi: 10.5217/ir.2018.00117
BACKGROUND/AIMS: The pharmacokinetics of tacrolimus (TAC) is known to be largely influenced by single-nucleotide polymorphisms (SNPs) in CYP3A5. Patients starting TAC require careful dose adjustment, owing to the wide range... -
- CITED
-
- Close
- SHARE
-
- Close
